Dianthus Therapeutics, Inc. /DE/ Proceeds from Maturities, Prepayments and Calls of Short-term Investments
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported Proceeds from Maturities, Prepayments and Calls of Short-term Investments of $23.00 million for the 6-month period ending 2024-06-30, per its 10-Q filed 2024-08-08.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments · last filed 2024-08-08
- Dianthus Therapeutics, Inc. /DE/ proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2024-06-30 was $8.00M, a 63.45% decline year-over-year.
- Dianthus Therapeutics, Inc. /DE/ proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2024-03-31 was $15.00M, a 31.82% decline year-over-year.
- Dianthus Therapeutics, Inc. /DE/ proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2023-12-31 was $18.00M, a 800.00% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2023-09-30 was $15.90M.
- Dianthus Therapeutics, Inc. /DE/ proceeds from maturities, prepayments and calls of short-term investments for fiscal 2023 was $77.78M, a 3789.25% increase from fiscal 2022.
- Dianthus Therapeutics, Inc. /DE/ proceeds from maturities, prepayments and calls of short-term investments for fiscal 2022 was $2.00M.
| Period end | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 3 month | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 6 month | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 9 month | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 12 month |
|---|---|---|---|---|
| 2024-06-30 | $8.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $23.00M 10-Q · filed 2024-08-08 | $41.00M derived: sum of 3 quarters · filed 2024-08-08 | $56.90M derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | $15.00M 10-Q · filed 2024-05-09 | $33.00M derived: sum of 2 quarters · filed 2024-05-09 | $48.90M derived: sum of 3 quarters · filed 2024-05-09 | $70.78M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-12-31 | $18.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $33.90M derived: sum of 2 quarters · filed 2024-03-21 | $55.78M derived: sum of 3 quarters · filed 2024-08-08 | $77.78M 10-K · filed 2024-03-21 |
| 2023-09-30 | $15.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $37.78M derived: sum of 2 quarters · filed 2024-08-08 | $59.78M 10-Q · filed 2023-11-09 | $61.78M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-06-30 | $21.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $43.88M 10-Q · filed 2024-08-08 | $45.88M derived: sum of 3 quarters · filed 2024-08-08 | |
| 2023-03-31 | $22.00M 10-Q · filed 2024-05-09 | $24.00M derived: sum of 2 quarters · filed 2024-05-09 | ||
| 2022-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $2.00M 10-K · filed 2024-03-21 | ||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $0.00 8-K · filed 2023-12-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |